FORGE MAGNET PLATFORM

FORGING NOVEL METALLOENZYME-TARGETING ANTI-INFECTIVES TO COMBAT
ANTIMICROBIAL RESISTANCE

Forge Therapeutics has built a proprietary platform called MAGNET (Metalloprotein-targeting Approach to Generating New Experimental Therapeutics) to discover novel-class anti-infectives. With a development candidate to treat infections caused by high-priority Gram-negative pathogens, Forge is advancing its portfolio with partners worldwide.

FORGE MAGNET PLATFORM:

STEP 1

Target screen of metal-binding pharmacophore (MBP) library to identify novel, selective inhibitors as starting points – MBP-C1

STEP 2

Model ‘hit’ MBPs coordinating to metal in active site and perform fragment growth with initial backbone – FG-770

STEP 3

Elaborate backbone for improved potency, selectivity, and drug-like properties – FG-960